NEW YORK and BERLIN, June 26, 2024 —  (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation are as follows:

Format: Virtual fireside chat and 1×1 investor meetings
Date and Time: Fireside chat available on-demand from Thursday, June 27 at 07:00 A.M. ET
Webcast link:

An archived replay will be available on the Investors section of the atai website under  for up to 90 days.

About atai Life Sciences

atai is a clinical-stage biopharmaceutical company focused on revolutionizing mental health disorder treatments. Established in response to the significant unmet need and lack of innovation in mental health treatment, atai is dedicated to developing innovative therapies for depression, anxiety, addiction, and other mental health conditions. By pooling resources and expertise, atai aims to responsibly accelerate the development of new medicines to achieve clinically meaningful and sustained behavioral change in mental health patients. atai’s vision is to heal mental health disorders so that everyone, everywhere can live a more fulfilling life. For more information, please visit .

Contact Information

Investor Contact:

Media Contact: